Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias
PharmacoEconomics · 2024
DOI: 10.1007/s40273-024-01418-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift PharmacoEconomics, 2024. Verfasst von Yankier Pijeira Perez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Health Economics and Medicines Evaluation, Bangor University, Ardudwy, Normal Site, Holyhead Road, Bangor, Gwynedd, Wales, LL57 2PZ, UK. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Bias. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HCRW, Medical Research Council, Health and Care Research Wales.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Centre for Health Economics and Medicines Evaluation, Bangor University, Ardudwy, Normal Site, Holyhead Road, Bangor, Gwynedd, Wales, LL57 2PZ, UK.
- Centre for Health Economics and Medicines Evaluation, Bangor University, Ardudwy, Normal Site, Holyhead Road, Bangor, Gwynedd, Wales, LL57 2PZ, UK. d.a.hughes@bangor.ac.uk.
ORCID-Profile: Yankier Pijeira Perez, Dyfrig A Hughes
Förderung
- HCRW
- Medical Research Council
- Health and Care Research Wales
Zitieren
APA
Pijeira Perez, Y., & Hughes, D. A. (2024). Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias. PharmacoEconomics. https://doi.org/10.1007/s40273-024-01418-3
Vancouver
Pijeira Perez Y, Hughes DA. Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias. PharmacoEconomics. 2024. doi:10.1007/s40273-024-01418-3
BibTeX
@article{PijeiraPerez2024,
author = {Pijeira Perez, Yankier and Hughes, Dyfrig A},
title = {Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias},
journal = {PharmacoEconomics},
year = {2024},
doi = {10.1007/s40273-024-01418-3}
}
EUVIMED